Home › NCT05630989

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Age ≥18 years.
2. Diagnosis of advanced pancreatic ductal adenocarcinoma as determined by the treating physician or tumor board.
3. Tumor must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician.
4. Ability to understand a written informed consent document and the willingness to sign it.

Exclusion Criteria:

1. Age \<18 years.
2. Primary cancer diagnosis other than advanced pancreatic ductal adenocarcinoma
3. Tumor does not have a KRAS G12R mutation.

About the study

This is an observational precision oncology study designed to collect and analyze data that allows us to characterize the safety and efficacy of several different mitogen-activated protein kinase kinase inhibitor (MEKi) -based treatment strategies and the feasibility of administering MEKi combination therapies to patients with KRAS G12R mutated advanced pancreatic ductal adenocarcinoma (PDAC).

What is being tested

• combination therapy with no MEKi (other)
• combination therapy with MEKi-HCQ (drug)
• combination therapy with MEKi-EGFRi (drug)
• combination therapy with MEKi. (drug)

Sponsor: Mandana Kamgar, MD · Participants: 80 · Started: Feb 7, 2023

Contact the study team

• Mandana Kamgar, MD, MPH · Phone: 414-805-4600

Official record on ClinicalTrials.gov — NCT05630989

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.